This content is from: Premium

Short Seller Bets on Scandal-Wracked MiMedx

Eiad Asbahi has taken a contrarian long position in the company — and at least one of his peers is highly skeptical.

When a company cans its CEO, gets its shares delisted and says its past financial statements may be fictions — well, perhaps it’s time to buy.That’s one takeaway from a report issued Tuesday by Eiad Asbahi, founder of activist short seller Prescience Point Capital Management, who is recommending buying shares

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content